Clinical Trial Update: A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and antiviral effect of oral FXR modulator EYP001a in chronic hepatitis B, in combination with pegylated interferon alpha-2a or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis B

Drugs mentioned

• EYP001a (EYP001a)

Snippet

Sponsor: Enyo Pharma | Conditions: Hepatitis B, Chronic | Phase 2 | Status: COMPLETED